CALTX — Calliditas Therapeutics AB Share News
0.000.00%
Last trade - 00:00HealthcareMid Cap
- SEK11.16bn
- SEK11.37bn
- SEK1.21bn
Brief: Calliditas Therapeutics AB Files For Mixed Shelf Of Up To $200 Million
Brief: Calliditas Therapeutics AB Announces Issuance And Repurchase Of C-Shares
Brief: Calliditas Therapeutics Receives Positive CHMP Opinion In IgA Nephropathy
Brief: Calliditas Q1 Operating Loss At SEK 208.4 Million
Brief: Calliditas Therapeutics: Regulatory Update On EMA Process For Nefecon
Brief: Calliditas Therapeutics: Updated Regulatory Plans For NEFECON In China
Brief: Calliditas Therapeutics Expands Licensing Agreement With Everest Medicine To South Korea
Brief: Everest Medicines Enters Into Agreement With Calliditas Therapeutics To Develop And Commercialize NEFECON
Brief: Calliditas Therapeutics Q4 Operating Loss At SEK 222.1 Million
Brief: FDA Grants Calliditas Therapeutics Accelerated Approval Of TARPEYO
NASDAQ RESUMED AT 04:31 PM
NASDAQ TRADE HALT HALT NEWS PENDING AT 03:07 PM
Brief: Calliditas Q3 Net Sales At SEK 198.2 Million
Brief: Calliditas Announces Acquisition Of Remaining Genkyotex Minority Shares
Brief: Calliditas Estimates Potential Impact Of 3 Months On Previous Timelines With An Expected Decision By EMA In Q1 2022
Brief: Calliditas Therapeutics AB Reports PDUFA Goal Date Extension For Nefecon NDA In U.S.
Brief: Calliditas Therapeutics Q2 Oper Loss Widens To SEK 159.4 Mln
Brief: Calliditas Receives FDA Fast Track Designation For Setanaxib
Brief: STADA And Calliditas Partner To Register And Commercialize Specialty Therapy For IgA Nephropathy in Europe